Smoking cessation in people with schizophrenia

Current Drug Abuse Reviews

Volumn 6, Issue 3, 2013, Pages 180-190

  Bennett, Melanie E ^a,b   Wilson, Amy L ^c   Genderson, Margo ^d   Saperstein, Alice M ^e  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VA Capitol Network Mental Illness Research Education and Clinical Center ^*  (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d BOSTON UNIVERSITY   (United States)

^e Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

Schizophrenia; Smoking cessation; Treatment

Indexed keywords

AMFEBUTAMONE; CLOZAPINE; HALOPERIDOL; PLACEBO; VARENICLINE;

ABSTINENCE; BEHAVIOR THERAPY; COGNITIVE THERAPY; DEPRESSION; HEALTH PROGRAM; HUMAN; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOLOGIC ASSESSMENT; PSYCHOSOCIAL CARE; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SCHIZOPHRENIA; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME; EPIDEMIOLOGY; PATHOPHYSIOLOGY; PREVENTION AND CONTROL; PROCEDURES; SMOKING; TIME; TOBACCO USE DISORDER;

HUMANS; QUALITY OF LIFE; SCHIZOPHRENIA; SMOKING; SMOKING CESSATION; TIME FACTORS; TOBACCO USE DISORDER;

EID: 84907103356     PISSN: 18744737     EISSN: 18744745     Source Type: Journal    
DOI: 10.2174/18744737112059990011     Document Type: Review

References (79)

1. De Leon J. Smoking vulnerability for schizophrenia. Schizophr Bull 1996; 22(3): 405-9.
2. De Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM. Schizophrenia and smoking: An epidemiological survey in a state hospital. Am J Psychiatry1995; 152(3): 453-55.
3. Glynn SM, Sussman S. Why patients smoke. Hosp Community Psych 1990; 41(9): 1027-28.
4. Goff DC, Henderson DC, Amico E. Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. Am J Psychiatry 1992; 149(9): 1189-94.
5. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986; 143: 993-97.
6. Kelly C, McCreadie RG. Smoking habits, current symptoms, and premorbid\characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry 1999; 156: 1751-57.
7. Llerena A, de la Rubia A, Penas-Lledo EM, Diaz FJ, & de Leon J. Schizophrenia and tobacco smoking in a Spanish psychiatric hospital. Schizophr Res 2003; 60(2-3): 313-7.
8. Tanskanen A, Viinamaki H, Koivumaa-Honkanen HTJ. Smoking among psychiatric patients. Eur Psychiat 1997; 11: 179-88.
9. Ziedonis DM, Kosten TR, Glazer WM, Frances RJ. Nicotine dependence and schizophrenia. Hosp Community Psych 1994; 45: 204-6.
10. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: A population-based prevalence study. JAMA 2000; 284(20): 2606-10.
11. Shopland DR, Hartman AM, Gibson JT, Mueller MD, Kessler LG, Lynn WR. Cigarette smoking among U.S. adults by state and region: Estimates from the current population survey. J Natl Cancer I 1996; 88: 1748-58.
12. Diwan A, Castine M, Pomerleau CS, Meador-Woodruff JH, Dalack GW. Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders. Schizophr Res 1998; 33(1-2): 113-18.
13. Lohr JB, Flynn K. Smoking and schizophrenia. Schizophr Res 1992; 8: 93-102.
14. Leonard S, Adams CE. Smoking cessation and schizophrenia. Am J Psychiatry 2006; 163 (11): 1877.
15. Compton MT, Daumit GL, Druss, BG. Cigarette smoking and overweight/obesity among individuals with serious mental illnesses: a preventive perspective. Harvard Rev Psychiat 2006; 14 (4): 212-22.
16. Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiat 2006; 67(11): e16.
17. Catts VS, Catts SV, O'Toole BI, Frost, ADJ. Cancer incidence in patients with schizophrenia and their first-degree relatives: A metaanalysis. Acta Psychiatr Scand 2008; 117(5): 323-36.
18. Lichtermann D, Ekelund J, Pukkala E, Tanskanen A, Lonnqvist J. Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiat 2001; 58: 573-78.
19. Tran E, Rouillon F, Loze JY, Philippe A, Vitry F, Limosin F. Cancer mortality in patients with schizophrenia. Cancer 2009; 115(15): 3555-62.
20. Harris AE. Physical disease and schizophrenia. Schizophr Bull 1988; 14(1): 85-96.
21. Tsuang MT, Perkins K, Simpson JC. Physical diseases in schizophrenia and affective disorder. J Clin Psychiat 1983; 44(2): 42-6.
22. Masterson E, O'Shea B. Smoking and malignancy in schizophrenia. Br J Psychiatry 1984; 145: 429-32.
23. Dixon L, Medoff DR, Wohlheiter K, DiClemente C, Goldberg R, Kreyenbuhl J, Adams C, Lucksted A, Davin MS. Correlates of severity of smoking among persons with severe mental illness. Am J Addiction 2007; 16(2): 101-10.
24. Ereshefsky L, Jann MW, Saklad SR, Davis CM, Richards AL, Burch NR. Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiat 1985; 20: 329-32.
25. Miller DD, Kelly MW, Perry PJ, Coryell WH. (1990). The influence of cigarette smoking on haloperidol pharmacokinetics. Biol Psychiat 1990; 28: 529-31.
26. Perry PJ, Miller DD, Arndt SV, Smith DA, Holman TL. Haloperidol dosing requirements: The contribution of smoking and nonlinear pharmacokinetics. J Clin Psychopharm 1993; 13: 46-51.
27. Salokangas RKR, Saarijarvi S, Taiminen T, Lehto H, Niemi H, Ahola V, Syvalahti E. Effect of smoking on neuroleptics in schizophrenia. Schizophr Res 1997; 23(1): 55-60.
28. Seppala NH, Leinonen EV, Lehtonen ML, Kivisto KT. (1999). Clozapine serum concentrations are lower in smoking than in nonsmoking schizophrenic patients. Pharmacol Toxicol 1999; 85(5): 244-46.
29. Shimoda K, Someya T, Mortia S, Hirokane G, Noguchi T, Yokono A, Shibasaki M, Takahashi S. Lower plasma levels of haloperidol in smoking that in nonsmoking schizophrenic patients. Ther Drug Monit 1999; 21(3): 293-296.
30. Vinarova E, Vinat O, Kalvach Z. Smokers need higher doses of neuroleptic drugs. Biol Psychiat 1984; 19: 1265-68.
31. Steinberg ML, Williams JM, Ziedonis DM. Financial implications of cigarette smoking among individuals with schizophrenia. Tob Control 2007; 13: 206.
32. Chou K, Chen R, Lee J, Ku C, Lu R. The effectiveness of nicotinepatch therapy for smoking cessation in patients with schizophrenia. Int J Nurs Stud 2004; 41: 321-30.
33. Williams JM, Ziedonis DM, Foulds J. A case series of nicotine nasal spray in the treatment of tobacco dependence among patients with schizophrenia. Psychiatr Serv 2004; 55(9): 1064-66.
34. Horst WD, Klein MW, Williams, D, Werder SF. Extended use of nicotine replacement therapy to maintain smoking cessation in persons with schizophrenia. Neuropsychiatric Disease and Treatment 2005; 1(4): 349-55.
35. Weiner E, Ball MP, Summerfelt A, Gold J, Buchanan RW. Effects of sustained release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am J Psychiatry 2001; 158(4): 635-37.
36. Addington J, el-Guebaly N, Campbell W, Hodgins DC, Addington D. Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry 1998; 155: 974-6.
37. Weiner E, Ball MP, Buchholz AS, Gold JM, Evins AE, McMohon RP, Buchanan RW. Bupropion sustained release added to group support for smoking cessation in schizophrenia: A new randomized trial and meta-analysis. J Clin Psychiat 2011; 73(1): 95-102.
38. Fatemi SH, Stary JM, Hatsukami DK, Murphy SE. A double-blind placebo-controlled cross over trial of bupropion in smoking reduction in schizophrenia. Schizophr Res 2005; 76(2-3): 353-56.
39. George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, Kosten TR. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiat 2002; 52(1): 53-61.
40. George TP, Vessicchio JC, Sacco KA, Weinberger AH, Dudas MM, Allen TM, Creeden CL, Potenza MN, Feingold A, Jatlow PI. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiat 2008; 63(11): 1092-96.
41. Evins AE, Mays VK, Rigotti NA, Tisdale T, Cather C, Goff DC. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res 2001; 3(4): 397-403.
42. Evins AE, Cather C, Deckersbach T, Freudenreich O, Culhane MA, Olm-Shipman CM, Henderson DC, Schoenfeld DA, Goff DC, Rigotti NA. A double-blind placebo controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharm 2005; 25(3): 218-25.
43. Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, Henderson DC, Schoenfeld DA, Rigotti NA, Goff D. A 12-week double-blind placebo controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharm 2007; 27(4): 380-86.
44. Smith RC, Lindenmayer JP, Davis JM, Cornwell J, North K, Gupta S, Sershen H, Lajitha A. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res 2009; 110: 149-55.
45. Weiner E, Buchholz A, Coffay A, Liu F, McMahon RP, Buchanan RW, Kelly DL. Varenicline for smoking cessation in people with schizophrenia: A double-blind randomized pilot study. Schizophr Res 2011; 129(1): 94-5.
46. McEvoy JP, Allen TB. The importance of nicotinic acetylcholine receptors in schizophrenia, bipolar disorder and Tourette's syndrome. Curr Drug Targets-CNS and Neurological Disorders 2002; 1(4): 433-42.
47. De Leon J, Diaz FJ, Josiassen RC, Cooper TB, Simpson GE. Does clozapine decrease smoking? Prog Neuro-Psychoph 2005; 29: 757-62.
48. Breckenridge JS. Smoking by outpatients [letter]. Hos Community Psych 1990; 41(4): 454-55.
49. Ziedonis DM, George TP. Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 1997; 23: 247-54.
50. George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, Rounsaville BJ, Kosten TR. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000; 157: 1835-42.
51. Chen R, Ku CH, Lu RB, Chou KR. The impact of smoking cessation programs on smoking-related health beliefs and rate of quit-smoking among schizophrenic patients. J Med Sciences 2002; 22(5): 215-20.
52. Baker A, Richmond R, Haile M, Lewin TJ, Carr VJ, Taylor RL, Jansons S, Wilhelm K. A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. Am J Psychiatry 2006; 163: 1934-42.
53. Currie SR, Karltyn J, Lussier D, de Denus E, Brown D, el-Guebaly N. Outcome from a community-based smoking cessation program for persons with serious mental illness. Community Ment Hlt J 2008; 44: 187-94.
54. Williams JM, Steinberg ML, Zimmermann MH, Gandhi KK, Stipelman B, Budsock PD, Ziedonis DM. Comparison of two intensities of tobacco dependence counseling in schizophrenia and schizoaffective disorder. J Subst Abuse Treat 2010; 38(4): 384-93.
55. Roll JM, Higgens ST, Steingard S, McGinley M. Use of monetary reinforcement to reduce the cigarette smoking of persons with schizophrenia: A feasibility study. Ex Clin Psychopharm 1998; 6(2): 157-61.
56. Tidey JW, O'Neill SC, Higgins ST. Contingent monetary reinforcement of smoking reductions, with and without transdermal nicotine, in outpatients with schizophrenia. Ex Clin Psychopharm 2002; 10(3): 241-47.
57. Gallagher SM, Penn PE, Schindler E, Layne W. A comparison of smoking cessation treatments for persons with schizophrenia and other serious mental illnesses. J Psychoactive Drugs 2007; 39(4): 487-97.
58. Dickerson F, Bennett M, Dixon L, Burke E, Vaughan C, Delahanty J, DiClemente C. Smoking cessation in persons with serious mental illnesses: The experience of successful quitters. Psychiatr Rehabil J 2011; 34(4): 311-16.
59. Himelhoch S, Daumit G. To whom do psychiatrists offer smokingcessation counseling? Am J Psychiatry 2003; 160(12): 2228-30.
60. Lucksted A, Dixon LB, Sembly JB. A focus group pilot study of tobacco smoking among psychosocial rehabilitation clients. Psychiatr Serv 2000; 51(12): 1544-48.
61. Carosella AM, Ossip-Klein DJ, Owens CA. Smoking attitudes, beliefs, and readiness to change among acute and long term care inpatients with psychiatric diagnoses. Addict Behav 1999; 24(3): 331-44.
62. Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: US Dept of Health and Human Services Public Health Service 2008.
63. Hall RG, Duhamel M, McClanahan R, Miles G, Nason C, Rosen S, Schiller P, Tao-Yonenaga L, Hall SM. Level of functioning, severity of illness, and smoking status among chronic psychiatric patients. J Nerv Ment Dis 1995; 183: 468-71.
64. Blanchard JJ, Mueser KT, Bellack AS. Anhedonia, positive and negative affect, and social functioning in schizophrenia. Schizophr Bull 1998; 24: 413-24.
65. Van Dongen CJ, Kriz P, Fox KA, Haque I. A quit smoking group. pilot study. J Psychosoc Nurs 1999; 37: 31-6.
66. Steinberg ML, Ziedonis DM, Krejci JA, Brandon TH. Motivational interviewing with personalized feedback: a brief intervention for motivating smokers with schizophrenia to seek treatment for tobacco dependence. J Consult Clin Psychol 2004; 72(4): 723-28.
67. Gray JA, Feldon J, Rawlins JNP, Hemsley DR, Smith AD. The neuropsychology of schizophrenia. Behav Brain Sci 1991; 14: 1-84.
68. Aharonovich E, Nunes E, Hasin D. Cognitive impairment, retention and abstinence among cocaine abusers in cognitive-behavioral treatment. Drug Alcohol Depen 2003; 71: 207-11.
69. Horner MD, Waid LR, Johnson DE, Latham PK, Anton RF. The relationship of cognitive functioning to amount of recent and lifetime alcohol consumption in outpatient alcoholics. Addict Behav 1999; 24(3): 449-453.
70. Bellack AS, Morrison RL, Mueser KT. Social problem solving in schizophrenia. Schizophr Bull 1989; 15: 101-16.
71. Bellack AS, DiClemente CC. Treating substance abuse among patients with schizophrenia. Psychiatr Serv 1999; 50: 75-80.
72. Hatashita-Wong M, Smith TE, Silverstein SM, Hull JW, Wilson DF. Cognitive functioning and social problem-solving skills in schizophrenia. Cognitive Neuropsych 2002; 7(2): 81-95.
73. Zanello A, Perring L, Huguelet P. Cognitive functions related to interpersonal Problem solving skills in schizophrenic patients compared with healthy subjects. Psychiat Res 2006; 142(1): 67-78.
74. Leonard S, Adams C, Breese CR, Adler LE, Bickford P, Byerley W, Coon H, Griffith JM, Miller C, Myles-Worsley M, Nagamoto HT, Rollins Y, Stevens KE, Waldo M, Freedman R. Nicotinic receptor function in schizophrenia. Schizophr Bull 1996; 22: 431-45.
75. Taiminen TJ, Salokangas RKR, Saarijarvi S, Niemi H, Lehto H, Ahola V, Syvalahti E. Smoking and cognitive deficits in schizophrenia: A pilot study. Addict Behav 1998; 23(2): 263-66.
76. Hackman AL, Goldberg RW, Brown CH, Fang L, Dickerson FB, Wohlheiter K, Medoff DR, Kreyenbuhl, JA, Dixon L. Use of emergency department services for somatic reasons by people with serious mental illness. Psychiatr Serv 2006; 57(4): 563-66.
77. Rosen-Chase C, Dyson V. Treatment of nicotine dependence in the chronic mentally ill. J Subst Abuse Treat 1999; 16(4): 315-320.
78. McEvoy J, Freundenreich O, McGee M, VanderZwaag C, Levin E, Rose J. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiat 1995; 37: 550-52.
79. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database of Systematic Reviews 2010; 16. CD007253. doi: 10.1002/14651858.CD007253.pub2.